Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
23 mai 2024 17h05 HE
|
Compass Therapeutics
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic...
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
14 mai 2024 08h00 HE
|
Compass Therapeutics
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
13 mai 2024 08h00 HE
|
Compass Therapeutics
Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment...
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
25 avr. 2024 08h00 HE
|
Compass Therapeutics
CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 study...
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
16 avr. 2024 08h00 HE
|
Compass Therapeutics
The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a...
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
12 avr. 2024 08h00 HE
|
Compass Therapeutics
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
10 avr. 2024 08h00 HE
|
Compass Therapeutics
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
09 avr. 2024 12h00 HE
|
Compass Therapeutics
Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of the fundamental...
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
21 mars 2024 09h00 HE
|
Compass Therapeutics
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
29 févr. 2024 08h00 HE
|
Compass Therapeutics
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...